ALDH7A1 and pulmonary arterial hypertension: Emerging data in carefully selected PAH patients suggests that up-front triple therapy with an ERA, PDE-Vi, and prostacyclin modulator is highly effective, and this topic is reviewed in greater detail elsewhere in this issue of the journal by Professor Simonneau.